Expanding RNAi Delivery to Muscle Tissue Through Antibody Oligonucleotide Conjugates

• Antibody-siRNA conjugates enable muscle-selective uptake, treating myopathies with minimal off-target effects
• Enhanced endosomal escape increases cytoplasmic siRNA release, improving dystrophin restoration in Duchenne MD
• Modular platform allows rapid re-targeting, accelerating therapies for multiple rare muscle disorders

Speakers:

Anthony Saleh

Chief Executive Officer

miRecule